Drug news
BMS transfers rights to Erbitux (cetuximab) in US, Puerto Rico and Canada to Eli Lilly.
Eli Lilly and Company and Bristol-Myers Squibb Company have announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers Squibb to Lilly. Rights include, but are not limited to, full commercialization and manufacturing operational responsibilities.
..Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.